This book provides an overview of the current knowledge on the pathophysiology, epidemiology and etiology of Waldenström’s macroglobulinemia (WM) and discusses how the disease may present, how it is diagnosed and when treatment should be initiated. An outline of current approaches to treatment as well as ongoing and planned research directions is also included. It contains a wealth of information for all members of the multidisciplinary team who care for patients with WM in the fields of hematology, oncology, gerontology, pathology and neurology.
This book offers the necessary information for patients diagnosed with Waldenström’s macroglobulinemia (WM) to engage in meaningful conversations with their healthcare providers. It empowers them to make informed decisions about managing their condition. Download this e-book to provide your patients with a deeper understanding of their illness.
Slide kit outlining the long-term follow-up of the ASPEN trial: Zanubrutinib vs. ibrutinib in patients with Waldenström’s macroglobulinemia (WM).
Factsheet summarising the long-term follow-up data of the ASPEN trial, a Phase 3 study of zanubrutinib vs ibrutinib in Waldenström’s macroglobulinemia (WM) patients.
Phase 2 study evaluating the safety of zanubrutinib in patients with B-cell malignancies who have become intolerant of prior ibrutinib and/or acalabrutinib treatment.